Do acute changes in heart rate by isoproterenol affect aortic stiffness in patients with hypertension?

Moo-Yong Rhee1, Na-Young Kwon, Jae-Deok Kim

  • 1Department of Internal Medicine, College of Medicine, Dankook University, Cheonan, Korea. rheemy@dankook.ac.kr

Insights

Acute changes in heart rate (HR) from isoproterenol do not significantly affect aortic stiffness in hypertensive patients. This suggests HR variations are not critical when measuring aortic pulse wave velocity (PWV).

Area of Science:

  • Cardiovascular Physiology
  • Hypertension Research
  • Vascular Mechanics

Background:

  • Increased aortic stiffness is a key risk factor for cardiovascular disease in hypertensive individuals.
  • Previous studies indicated heart rate (HR) changes during pacing do not impact aortic stiffness.
  • The effect of sympathomimetic-induced acute HR changes on aortic stiffness in hypertension remains unclear.

Purpose of the Study:

  • To investigate the impact of acute heart rate (HR) alterations induced by isoproterenol on aortic stiffness.
  • To determine if acute HR changes influence aortic stiffness measurements in patients with hypertension.

Main Methods:

  • Seventeen hypertensive patients participated after discontinuing vasoactive drugs.
  • Carotid-to-femoral pulse wave velocity (PWV) was measured using the foot-to-foot method.
  • PWV, compliance (C), and compliance index (Ci) were assessed at baseline and with incremental isoproterenol doses to increase HR; percent changes (delta) were analyzed.

Main Results:

  • No significant differences were observed in deltaPWV, deltaC, or deltaCi across groups based on HR changes (p > 0.05).
  • Regression analysis revealed no significant correlation between deltaHR and deltaPWV or deltaC (r = 0.18, 0.13; p > 0.05).
  • A weak correlation was found between deltaHR and deltaCi (r = 0.22, p < 0.05), explaining only 4.6% of the variance (r² = 0.046).

Conclusions:

  • Acute changes in heart rate (HR) induced by isoproterenol do not significantly alter aortic stiffness in hypertensive patients.
  • These findings suggest that acute HR variations do not necessitate consideration during aortic pulse wave velocity (PWV) measurements.
  • Aortic stiffness assessment via PWV may be reliable despite acute HR fluctuations in hypertensive individuals.
Abstract

Related Concept Videos

Factors Influencing Heart Rate01:30

Factors Influencing Heart Rate

The heart rate, or pulse rate, is a vital indicator of cardiovascular health. It reflects the number of times the heart beats per minute. Various physiological and environmental factors influence heart rate, increasing or decreasing cardiac output. Understanding these factors is crucial for assessing heart function and identifying potential health issues.
Let us explore the significant factors affecting heart rate, including age, body temperature, posture, acute pain, chemical influences,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Action of &#946;1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antihypertensive Drugs: Types of &#946;-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...